Orexo AB
(OTCQX: ORXOY)
|
7:21 PM UTC, 08/30/24 | |||
---|---|---|---|---|
Last: $1.51 | Change: +0.02 | %Change: +1.48% | Volume: 508 |
Open: | $ 1.77 | Volume: | 508 | |
---|---|---|---|---|
High: | $ 1.77 | Yield(%) | n/a | |
Low: | $ 1.51 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | n/a | |
EPS ($) | n/a | Shares Out: | n/a |
% Price Change (last 4 weeks): | n/a |
---|---|
% Price Change (last 13 weeks): | n/a |
% Price Change (last 26 weeks): | n/a |
% Price Change (last 52 weeks): | n/a |
% Price Change (year to date): | n/a |
Return on Equity (%): | n/a |
---|---|
Return on Assets (%): | n/a |
Return on Invested Capital (%): | n/a |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | n/a |
50-day Moving Average: | $1.39 |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | 812 |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $2.35 |
52-wk low: | $1.27 |
Bid: | $n/a |
Ask: | $n/a |
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. It operates through the following segments: US Pharma, Digital Therapeutics (DTx), and HQ and Pipelines. The US Pharma segment include sales of own pharmaceuticals in the US. The DTx segment comprises digital therapeutic venture. The HQ and Pipeline segment focuses in the out-licensed pharmaceuticals and costs for research and development, business development, global regulatory, and supply chain. The company was founded by Thomas Lundqvist on November 18, 1994 and is headquartered in Uppsala, Sweden.
|
Earnings (1year) ($): | n/a |
---|---|
Annual Dividend ($): | n/a |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | n/a |
Cash Flow ($): | n/a |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | n/a |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | n/a |
---|---|
Current Ratio (x): | n/a |
LT Debt/Equity (x): | n/a |
Total Debt/Equity (x): | n/a |